Eremid Genomic Services is pleased to announce a new research collaboration with BioCytics focused on advancing novel, immune-based cancer cell therapies. This initiative unites BioCytics’ innovative cell therapy platform with Eremid’s specialized genomic expertise to tackle critical challenges in next-generation oncology.
Through this partnership, Eremid will deploy its advanced single-cell transcriptomics pipeline to generate high-resolution genomic insights from complex cellular samples. By characterizing these immunotherapies at the individual cell level, the study seeks to reveal key biological mechanisms, helping to optimize therapeutic design and streamline clinical development.
The complete joint announcement, including additional details on the study’s scope and research milestones, is now available.
